Compare Regeneron Pharmaceuticals Inc (REGN) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Invesco S&P 500 High Div Low Volatility ETF trades at $52.39. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none, and Invesco S&P 500 High Div Low Volatility ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | SPHD | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | — |
52-Week High | $812.27 | $53.18 |
52-Week Low | $545.46 | $46.96 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
SPHD trades at $52.39, down 0.91% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on high-dividend, low-volatility S&P 500 stocks, offering a 4.5% 30-day SEC yield. Recent news highlights its appeal for income investors seeking stability amid market volatility, with monthly dividends of $0.21 per share.
Outlook remains stable for income-focused portfolios, with consistent dividend payments since 2012. Key risks include underperformance versus broader market indices and sensitivity to interest rate changes. Analyst sentiment is neutral, emphasizing its role in conservative income strategies rather than growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
